News

Trump imposes 100% tariff on imported drugs

Add Ticker News on Google
In this story

Trump imposes 100% tariffs on imported drugs, but CSL benefits from key exemptions in U.S. pharmaceutical imports

President Donald Trump has signed an executive order imposing a 100% tariff on imported patented pharmaceuticals and their active ingredients.This move aims to incentivize drug manufacturers to increase production in the U.S.

The tariffs are imposed under Section 232 of the Trade Expansion Act of 1962 for national security reasons.

Certain major pharmaceutical companies, including Pfizer and Merck, will not face tariffs due to confidential agreements with the White House.

Companies that commit to approved onshoring plans will incur a reduced 20% tariff.

Those without any agreements will be subject to the full 100% tariff.

Countries with trade agreements with the U.S. will benefit from lower rates, with tariffs from the EU at 15% and from the UK at 10%.

Generic drugs and biosimilars are exempt from tariffs for at least one year.

Australia’s industry

Australia’s pharmaceutical exports may face the 100% or 20% tariffs depending on company negotiations.

CSL, Australia’s largest drug exporter, is exempt from the tariffs on plasma-derived therapies.

CSL operates over 300 plasma collection centres in the U.S. and plans a $1.5 billion expansion in Illinois.

Tariffs will not take immediate effect, allowing large companies 120 days and smaller firms 180 days before implementation.

The announcement coincides with the administration’s focus on lowering drug prices before the 2026 midterm elections.

The tariffs result from a Section 232 investigation that began in April 2025 regarding dependence on imported patented drugs.

Tariffs and trade

The order aims to reshape the pharmaceutical landscape in the U.S.

It reflects ongoing tensions with global trading partners over drug pricing strategies.

The impact on health care in the U.S. may become a contentious topic in upcoming political discussions.

Industry stakeholders are closely monitoring the developments and potential repercussions for pharmaceutical access.

Up next
Could tax cuts deliver a better deal for hospitality businesses and workers?

Victoria’s hospitality industry is facing growing pressure from rising employment costs, with business operators.

Read the story →

Comments

No comments yet. Start the conversation.

Comments are checked before they appear. Keep it civil, and please don't make claims about people you can't back up.

Ticker Today takes a daily view of the world of news, politics and business.With Ahron YoungWhisky & Suits explores law, property finance and business over fine whisky.With Imran Khan and Chris ChristofiThe Founders Method explores practical lessons and systems for entrepreneursWith Jonathan Byrt and Jesse LeeworthyThe Connector explores property and urban growth across Australia and the UK.With Belinda CoateThe Property Playbook delivers research-led insights for property investors.With Tim Graham and Terry RyderState of Hospitality explores the challenges facing Australia's hospitality.With Jeremy KoadlowBuying Power helps young professionals enter property and build lasting wealth.With Victor and Reshmi KumarThe Airport Economist explores global trade, business and economic outlooks.With Tim HarcourtMedia Movers explores the trends shaping Australia's media and global news.With James ManningBroker Business explores strategies to build, grow and sustain a business.With Rex AfrasiabiMoney Matters explores practical financial strategies to build lasting wealth.With Dr Steven EnticottBeyond Education explores the ideas and technology shaping future learning.With Greg CampitelliTicker Air explores the latest aviation news, travel trends and developments.With Ahron YoungEarly Years Dialogue explores the issues shaping Australia's early learning.With Paul MondoMarkets and Machines explores AI, regulation and trends shaping the markets.With Chris BergSocial Intelligence explores how social media and AI transform our daily lives.With Dr Karen SutherlandThe AI Edge explores how artificial intelligence reshapes the world economy.With Brad Gastwirth

More from Ticker

Watch

More in News

View all →